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junction (CEJ), with exposure of the root surfa-
ce, leading to pain, unfavorable aesthetic appe-
arance and root caries. Surgical root coverage 
is the only therapeutic choice if cause-specific 
measures are insufficient to correct the defor-
mity of gingival mucose1.
Epiregulin (Epi) is a broad specificity EGF 
(epidermal growth factor) family member with 
the unique characteristic to transmit a more po-
tent mitogenic signal than EGF itself by binding 
all possible ErbB receptor complexes2,3, thus, sti-
mulating cell proliferation in various cellular li-
nages, such as keratinocytes and fibroblasts4,5.
Gum wound healing is important for both pe-
riodontal pathologies and surgery: for this rea-
son, it is conceivable a beneficial effect of Epi as 
treatment of gingival recession, considering the 
mounting evidence suggesting also a crucial role 
of Epi in mediating proliferation and migration of 
gingival epithelial cells and fibroblasts6. 
The aim of the present study was to design an 
innovative nanotechnological approach to deliver 
Epi directly to the gingival pocket, where its po-
sitive effect on cell proliferation and migration is 
needed.
Nanotechnology has gained significant clinical 
interest in recent years, and nanoparticles (NPs) 
have become very attractive to the pharmaceutical 
and biomedical fields as drug delivery vehicles7.
NPs can deliver a plethora of drugs, vaccines or 
biological macromolecules. By acting as drug de-
livery systems, NPs allow both a targeted admini-
stration of the active component to specific organ 
or cells and a controlled release of the drug7-9.
Moreover, biodegradable polymeric NPs repre-
sent a useful delivery device as they can protect 
drug moieties from enzymatic disruption and 
provide sustained drug release over a certain time 
in a controlled manner, reducing side effects and 
dosage of therapeutic agents8,10-12.
Abstract. – OBJECTIVE: Epiregulin is a mem-
ber of the epidermal growth factor (EGF) family 
produced by keratinocytes: the aim of this study 
was to investigate the ability of biocompatible 
nanoparticles loaded with such growth factor to 
increase human keratinocytes proliferation. 
MATERIALS AND METHODS: Different PLGA 
(Poly-d,l-lactide-co-glycolide)-nanoparticles 
(NPs) formulations have been characterized in 
size and zeta potential by dynamic light scat-
tering (DLS) analysis. The ability of the different 
PLGA-NPs formulations to adhere onto dental 
surfaces has been tested, and epiregulin-en-
riched PLGA-NPs has been produced. Epireg-
ulin release from NPs has been tested by en-
zyme-linked immunosorbent (ELISA) assay and 
the proliferative effects of epiregulin-NPs on hu-
man keratinocytes have been evaluated.
RESULTS: DLS analysis revealed a different size 
distribution depending on the PLA/PGA (poly lactic 
acid/poly glycolic acid) ratio used. 50:50 PLGA-NPs 
exhibited the smaller size and the best dental adhe-
sive ability. Moreover, such epiregulin-loaded NPs 
was able to increase cell proliferation.
CONCLUSIONS: Direct dental pocket drug de-
livery implies the NPs solution loading onto the 
dental surface at the cement-enamel junction 
level: 50:50 PLGA-NPs, with their small size and 
excellent adhesive ability, represent an interest-
ing tool to deliver epiregulin directly where there 
is the need for epithelial proliferation. These re-
sults describe a possible strategy for periodon-
tal pocket delivery of Epiregulin-loaded PL-
GA-NPs and might provide a new approach for 
the treatment of gingival recession, where gingi-
val epithelium proliferation is needed.
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Introduction
Gum recession is defined as the shift of the 
marginal tissue apical to the cement-enamel 
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Poly-d,l-lactide-co-glycolide (PLGA) is one of 
the most successfully used polymer to develop 
drug delivery systems, thanks to its attractive pro-
perties, such as favorable mechanical characteri-
stics, biodegradability and biocompatibility, and 
FDA (US Food and Drug Administration) appro-
val for human usage.
PLGA-NPs are biodegradable in the body: they 
undergo hydrolysis, leading to the production of 
the original monomers lactic acid and glycolic acid, 
that are metabolized via the Krebs cycle8,9,12,13. 
In the present study, epiregulin-enriched PL-
GA-NPs was produced and characterized. Once 
identified the formulation assuring the best adhe-
sion on the dental surface, epiregulin-loaded NPs 
was produced and tested to evaluate growth fac-
tor release and its ability to modulate cell prolife-




Healthy adult teeth were obtained from 
“S.C.D.U. Odontoiatria e Stomatologia”, of the 
“Maggiore della Carità” Hospital (Novara, Italy) 
after routine extraction with written informed 
consent obtained from patients. The study was 
approved by the Ethical Committee of “Maggiore 
della Carità” Hospital in Novara, ALS of Biella, 
Novara, Vercelli and Verbano-Cusio-Ossola (stu-
dy n. CE 63/11).
Soon after extraction, teeth were immersed in 
a 0.2% chlorhexidine solution for 30 minutes and 
then stored at 4°C in phosphate-buffered saline 
(PBS) solution (pH = 7.4) during the study period.
PLGA-nanoparticles Production
PLGA-NPs were prepared by a modified 
double solvent evaporation method14. Briefly, 
60 mg of PLGA (50:50, 65:35, 75:25) crystals 
(Sigma-Aldrich, Saint Luis, MO, USA) were 
dissolved in 1 ml of dichloromethane (DCM) 
(Sigma-Aldrich, St. Luis, MO, USA) at room 
temperature. To produce control NPs, 50 µl of 
1% polyvinyl alcohol (PVA) (Sigma-Aldrich, St. 
Luis, MO, USA) aqueous solution were added 
to PLGA and the solution was sonicated for 1 
min. After that, 5 volumes of 1% PVA aqueous 
solution were carefully added to the resulting 
emulsion in order to maintain phase separation. 
A further 2 min sonication was performed to 
obtain the final emulsion that was evaporated 
overnight under fume hood, to remove DCM. 
The resulting NPs were washed 5 times in di-
stilled water by centrifugation at 13000 rpm for 
5 min, resuspended in water and stored at 4oC. 
NPs containing epiregulin were produced as 
above by adding 50 µl Epi (human recombinant 
epiregulin, E. coli derived, R&D Systems, Min-
neapolis, MN, USA, 50 ng/ml), instead of PVA, to 
the PLGA solution dissolved in DCM during the 
first step of the preparation. 
Particle Size and Zeta Potential 
Measurement
Particle size and polydispersity index after water 
dispersion and the charge density exposed on the 
surface of PLGA-NPs were evaluated by using DLS 
(dynamic light scattering) technique. PLGA-NPs 
were dispersed in water (1 mg/ml) and measured 
through DLS analysis in order to determine the 
particle size distribution. DLS experiments were 
carried out using a Zetasizer Nano ZS instrument 
(Malvern Instruments Ltd, Malvern, UK), operating 
in a particle size range from 0.6 nm to 6 μm and 
equipped by a laser He-Ne with λ = 633 nm. Zeta 
potential analysis (ζ-potential), carried out to deter-
mine the stability behavior of our NPs solutions, was 
performed using the same instrument.
NPs adhesion to Dental Surface
In order to evaluate the NPs adhesion onto 
the dental surface, teeth were photographed be-
fore and after NPs loading, testing three different 
PLA/PGA (poly lactic acid/poly glycolic acid) 
ratio formulations (50:50, 65:35 and 75:25) in or-
der to determine the best PLGA grade in terms 
of dental surface adhesion. The NPs suspension 
was positioned at the CEJ level, let dry and pho-
tographed. NPs-loaded teeth were then incubat-
ed in simulated saliva15 at 37°C for 3 hours in 
order to simulate the oral cavity real conditions. 
Then, digital pictures of each tooth were captured 
for comparison and NPs attachment areas were 
quantified using ImageJ software (U. S. National 
Institutes of Health, Bethesda, MD, USA). NPs 
covered area after incubation, was expressed as 
the percentage of the initial area at time zero ± 
standard deviation (SD). 
Epiregulin Release Assay
As dental adhesion and particle size results 
indicate the optimal PLA/PGA polymer ratio to 
be 50:50, we produced 50:50 PLGA-NPs contain-
ing Epiregulin and analyzed its release profile by 
enzyme-linked immunosorbent assay (ELISA) 
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(Uscn Life Sciences Inc., Wuhan, China). Briefly, 
Epi-enriched NPs have been incubated in simu-
lated saliva at 37°C and at fixed time points (3h, 
6h, 1, 2, 10 days) simulated saliva aliquots of 100 
µl for each sample have been assayed following 
manufacturer’s instructions; the optical density 
(O.D.) was read at 450 nm on a microplate reader. 
Results were expressed as mean values ± standard 
deviation (SD).
Cell Culture
Spontaneously immortalized keratinocytes 
(HaCaT, CLS Cell Lines Service GmbH, Ep-
pelheim, Germany), isolated from human adult 
skin16, were grown in culture flask (75 cm2) in 
DMEM medium (Euroclone, Milan, Italy) supple-
mented with 10% heat-inactivated foetal bovine 
serum (FBS) (Euroclone, Milan, Italy), penicillin 
(100 U/ml), streptomycin (100 mg/ml) and L-glu-
tamine (2 mM) (Euroclone, Milan, Italy) in a hu-
midified atmosphere containing 5% CO2 at 37°C. 
Cell Proliferation Assay
To evaluate the proliferative effects of epiregu-
lin released from PLGA-NPs, HaCaT cells were 
seeded in 24-well plates at a density of 2x104 cel-
ls/well and incubated in the presence or absence 
of PLGA-NPs supernatant, obtained after Epi-lo-
aded and unloaded NPs solution centrifugation. 
Such samples were diluted 1:4 in Dulbecco’s 
Modified Eagle’s Medium (DMEM) before cell 
treatment. As NPs supernatant main component 
is represented by water, cells were also treated 
with the same volume of water in order to exclude 
vehicle interference. After 72h of incubation, cel-
ls were fixed in 3.7% formaldehyde-3% sucrose 
solution and stained with 1% toluidine blue solu-
tion. Stained samples were photographed at 10X 
magnification, using an optical microscope (Leica 
ICC50HD, Leica Microsystems Wetzlar GmbH, 
Wetzlar, Germany) and cell proliferation was 
evaluated by counting cells in 10 random fields 
in three samples for each experimental condition. 
Results were expressed as cells/mm2 ± standard 
deviation (SD).
Statistical Analysis
Unpaired Student’s t-tests were used for sta-
tistical analysis. Statistical evaluation was per-
formed with the Prism 4.0 statistical software 
(GraphPad Software Inc., La Jolla, CA, USA). 




NPs size distribution analysis by DLS approa-
ch revealed a different size distribution depending 
on the formulation (i.e. PLA/PGA ratio). In parti-
cular, the 50:50 PLGA-NPs formulation displayed 
the smallest size among the three formulations 
analyzed (Table I). In general, particle aggrega-
tion is less likely to occur for charged particles 
(high zeta potential) due to electric repulsion. The 
zeta potential found here for the different NPs for-
mulations suggest that there was no difference in 
the surface charge characteristics of these NPs, 
but might allow particles aggregation. Neverthe-
less, these data do not indicate that NPs suspen-
sion is unstable, as the hydrophilicity of PLGA is 
sufficient to maintain the particles suspended.
PLGA NPs Adhesion to Dental Surface 
NPs ability to adhere to the dental surface is an 
essential feature allowing their direct placement 
at the CEJ level; for this reason, the different PL-
GA-NPs formulations ability to adhere on teeth 
was evaluated.
As shown in Figure 1, 50:50 PLGA-NPs ex-
hibited the best dental adhesion ability. Indeed, 
after 3h of incubation in artificial saliva, 50:50 
PLGA-NPs were still present onto the dental sur-
face covering an area of 87.6 ± 1.2% compared to 
time zero (NPs freshly applied onto the teeth). On 
the contrary, the other PLGA formulations (65:35 
and 75:25) have shown a statistically significant 
reduction (p<0.001) in the attachment area.
As 50:50 PLGA-NPs displayed the better adhe-
sion ability on dental surface, growth factor load-
ed NPs were produced using such scaffold.
In vitro Epiregulin Release
Quantification of epiregulin release from PL-
GA-NPs performed by ELISA assay indicates that 
Epi-enriched NPs incubated in simulated saliva at 
37°C were able to produce a peak in Epi release 
after 3 hours of incubation (Figure 2). At this time 
point, 88 ± 25 pg/ml of Epi have been detected, 
Table I. Size and zeta potential. Size and zeta potential of 
the different PLGA-NPs formulations analyzed by dynamic 
light scattering.
PLGA NPs Size Zeta potential
50:50 190 nm (PDI=0.093) -5.91 mV (SD=3.95 mV)
65:35 220 nm (PDI=0.235) -3.20 mV (SD=3.54 mV)
75:25 370 nm (PDI=0.617) -4.49 mV (SD=11.10 mV)
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while a significant reduction (p<0.05) and a sta-
bilization of the Epi release levels occurred at the 
following time points.
Epiregulin Released from PLGA NPs 
Stimulates Cell Proliferation
As shown in Figure 3, a statistically signifi-
cant (p<0.01) increase in cell proliferation occurs 
only in the samples treated with Epi-enriched PL-
GA-NPs supernatant while unloaded NPs super-
natant did not affect cell proliferation. Therefore, 
even if epiregulin released by NPs is very low, it 
was sufficient to induce an increase in cell proli-
feration compared to control conditions.
Discussion
Gingival recession or marginal tissue recession 
is a pathological condition defined as the location 
Figure 1. NPs adhesion to dental surface. A) Digital pictures of teeth immediately after NPs loading (T0), and after 3 hours 
(T1) of incubation in simulated saliva. B) Quantification of NPs attachment areas on the different PLGA formulations. Data are 
expressed as percentage ± SD of the initial filled area (**p<0.001).
Figure 2. Epiregulin release assay. Quantification of epiregulin release from 50:50 PLGA-NPs performed by ELISA assay 
(*p<0.05).
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of the marginal tissue apical to the cement-ena-
mel junction with exposure of the root surface.
Gum recession is a quite common condition af-
fecting a large number of persons worldwide, in-
cluding both dentally aware populations and tho-
se with limited access to dental care. Its etiology 
is multifactorial and its management is generally 
based on a thorough assessment of the causative 
factors and the degree of involvement of tissues.
From a clinical point of view, different surgical 
procedures exist to manage such condition. 
When gum recession is treated by a surgi-
cal approach, techniques used for root coverage 
mainly focus on tissue displacement to increase 
the width of keratinized tissue, in order to solve 
poor aesthetics or root hypersensitivity1.
One of the major drawbacks of surgery is re-
presented by the presence of wounds, along with 
creeping attachment of free gingival grafts and 
possible complications.
Literature data show that localized drug deli-
very systems might represent a very interesting 
tool for the treatment of periodontal diseases as 
they can lead to lower incidence of side effects 
and enhanced patient compliance17,19.
Epiregulin is a member of the EGF growth 
factor family known to stimulate keratinocytes 
proliferation19. As it can also regulate epithelial 
cells and fibroblast proliferation, it might also 
play a crucial role in gingival tissue wound he-
aling, finally leading to the reconstruction of the 
damaged extracellular matrix and to fill damaged 
connective tissue forming the granulation tissue6. 
An innovative nanotechnological approach for 
the treatment of gum recession could be repre-
sented by the direct delivery and release of Epi 
directly in the periodontal pocket.
To obtain such effect, polymeric NPs could 
represent an interesting vehicle, as their size re-
present an important determinant for drug release 
and NPs degradation, finally affecting the effi-
cacy of the therapeutic agent14,20-22.
In this study, different PLA/PGA ratio for-
mulations were tested. DLS analysis demonstra-
ted that 50:50 PLGA-NPs exhibit the lowest size 
compared to 65:35 and 75:25 formulations, sugge-
sting a more efficiently cellular uptake than larger 
size formulations. 
The degradation rate of NPs depends on the hy-
drophilicity of the polymer. As lactic acid is more 
hydrophobic than glycolic acid, it slows down the 
degradation process of lactide-rich PLGA copoly-
mers21. Therefore, 50:50 PLGA-NPs also display 
the fastest degradation rate in vivo, compared to 
the other PLGA formulations, which is a desirable 
result for patients13,21.
As direct dental pocket drug delivery implies 
the NPs solution loading onto the dental surface 
Figure 3. Cell proliferation. A) Cellular proliferation of treated cells assessed by manual count. Results are expressed as me-
ans ± SD (**p<0.01). B) Optical microscopy images of HaCaT cells grown in presence or absence of NPs supernatant. A= cnt, 
untreated cells; B= H2O-treated cells; C= NPs supernatant treated cells; D= Epi-NPs supernatant treated cells.
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at the CEJ level, their ability to adhere onto dental 
surface is a characteristic of a major significance.
In the present study, different PLGA-NPs for-
mulations ability to adhere onto the dental surface 
in experimental conditions simulating the oral ca-
vity condition were tested, in order to identify the 
best NPs to be loaded with epiregulin.
50:50 PLGA-NPs showed the lowest particle 
size, associated to the better adhesion ability; for 
these reasons they were chosen as the vehicle for 
epiregulin. 
The in vitro Epi release from PLGA-NPs reve-
aled a peak in growth factor release after 3 hours 
of incubation in simulated saliva. Epi released 
from NPs was tested for its ability to modulate 
keratinocytes proliferation, demonstrating that, 
although released levels were low, a significant 
cell proliferation stimulation occurs.
Results described herein agree with a previous 
study [4] indicating that an epiregulin dose as low 
as 0.05 ng/ml is sufficient to induce a significant in-
crease in cell proliferation in human keratinocytes.
Conclusions
Even if more in vitro and in vivo investigations 
are needed, preliminary data described herein 
suggest that 50:50 Epi-enriched PLGA-NPs could 
provide a new tool for the treatment of gingival 
recession.
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